...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Shareholders

As I posted a few weeks ago, one of my brokerages is looking at this.  As per their latest update, the complaint has gone out to the third party data vendor(s) and the brokerage is waiting for confirmation of changes.  I suspect we'll see some corrections at brokerages and stock market sites once it's fixed.

Share
New Message
Please login to post a reply